In the field of reproductive development, male idiopathic hypogonadotropic hypogonadism (IHH) is a rare disease. Suffering from this disease will affect the patient's reproductive function and quality of life, and requires hormone replacement therapy for up to 1-2 years or even lifelong.

The company's recombinant human follicle-stimulating hormone-CTP fusion protein injection is the first long-acting weekly recombinant gonadotropin preparation approved for clinical trial in the treatment of IHH in China. Related research will provide better treatment options for IHH patients. During the reporting period, the company continued to promote the clinical trial of recombinant human follicle-stimulating hormone-CTP fusion protein injection in combination with human chorionic gonadotropin (hCG) for the treatment of adolescent males aged 14-18 years (excluding 18 years old) with idiopathic hypogonadotropic hypogonadism (IHH).